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Articles
Global patterns in monthly activity of influenza virus, 
respiratory syncytial virus, parainfluenza virus, and 
metapneumovirus: a systematic analysis
You Li, Rachel M Reeves, Xin Wang, Quique Bassat, W Abdullah Brooks, Cheryl Cohen, David P Moore, Marta Nunes, Barbara Rath, 
Harry Campbell, Harish Nair, on behalf of the RSV Global Epidemiology Network and RESCEU investigators*
Summary
Background Influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus are the most 
common viruses associated with acute lower respiratory infections in young children (<5 years) and older people 
(≥65 years). A global report of the monthly activity of these viruses is needed to inform public health strategies and 
programmes for their control.
Methods In this systematic analysis, we compiled data from a systematic literature review of studies published between 
Jan 1, 2000, and Dec 31, 2017; online datasets; and unpublished research data. Studies were eligible for inclusion if they 
reported laboratory-confirmed incidence data of human infection of influenza virus, respiratory syncytial virus, 
parainfluenza virus, or metapneumovirus, or a combination of these, for at least 12 consecutive months (or 52 weeks 
equivalent); stable testing practice throughout all years reported; virus results among residents in well-defined 
geographical locations; and aggregated virus results at least on a monthly basis. Data were extracted through a three-
stage process, from which we calculated monthly annual average percentage (AAP) as the relative strength of virus 
activity. We defined duration of epidemics as the minimum number of months to account for 75% of annual positive 
samples, with each component month defined as an epidemic month. Furthermore, we modelled monthly AAP of 
influenza virus and respiratory syncytial virus using site-specific temperature and relative humidity for the prediction of 
local average epidemic months. We also predicted global epidemic months of influenza virus and respiratory syncytial 
virus on a 5° by 5° grid. The systematic review in this study is registered with PROSPERO, number CRD42018091628.
Findings We initally identified 37 335 eligible studies. Of 21 065 studies remaining after exclusion of duplicates, 
1081 full-text articles were assessed for eligibility, of which 185 were identified as eligible. We included 246 sites for 
influenza virus, 183 sites for respiratory syncytial virus, 83 sites for parainfluenza virus, and 65 sites for 
metapneumovirus. Influenza virus had clear seasonal epidemics in winter months in most temperate sites but 
timing of epidemics was more variable and less seasonal with decreasing distance from the equator. Unlike influenza 
virus, respiratory syncytial virus had clear seasonal epidemics in both temperate and tropical regions, starting in late 
summer months in the tropics of each hemisphere, reaching most temperate sites in winter months. In most 
temperate sites, influenza virus epidemics occurred later than respiratory syncytial virus (by 0·3 months [95% CI 
–0·3 to 0·9]) while no clear temporal order was observed in the tropics. Parainfluenza virus epidemics were found 
mostly in spring and early summer months in each hemisphere. Metapneumovirus epidemics occurred in late 
winter and spring in most temperate sites but the timing of epidemics was more diverse in the tropics. Influenza 
virus epidemics had shorter duration (3·8 months [3·6 to 4·0]) in temperate sites and longer duration (5·2 months 
[4·9 to 5·5]) in the tropics. Duration of epidemics was similar across all sites for respiratory syncytial virus 
(4·6 months [4·3 to 4·8]), as it was for metapneumovirus (4·8 months [4·4 to 5·1]). By comparison, parainfluenza 
virus had longer duration of epidemics (6·3 months [6·0 to 6·7]). Our model had good predictability in the average 
epidemic months of influenza virus in temperate regions and respiratory syncytial virus in both temperate and 
tropical regions. Through leave-one-out cross validation, the overall prediction error in the onset of epidemics was 
within 1 month (influenza virus −0·2 months [−0·6 to 0·1]; respiratory syncytial virus 0·1 months [−0·2 to 0·4]).
Interpretation This study is the first to provide global representations of month-by-month activity of influenza virus, 
respiratory syncytial virus, parainfluenza virus, and metapneumovirus. Our model is helpful in predicting the local 
onset month of influenza virus and respiratory syncytial virus epidemics. The seasonality information has important 
implications for health services planning, the timing of respiratory syncytial virus passive prophylaxis, and the 
strategy of influenza virus and future respiratory syncytial virus vaccination.
Funding European Union Innovative Medicines Initiative Respiratory Syncytial Virus Consortium in Europe (RESCEU).
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
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Introduction
Influenza virus, respiratory syncytial virus, parainfluenza 
virus, and metapneumovirus are the four major viral 
pathogens associated with acute lower respiratory 
infection and these represent a substantial burden of 
disease particularly in young children (<5 years)1 and older 
people (≥65 years).2,3 Globally, influenza virus is estimated 
to cause 39·1 million acute lower respiratory infection 
episodes (95% uncertainty interval 30·5–48·4) and 
58 200 deaths (44 000–74 200) annually; and respiratory 
syncytial virus is estimated to cause 24·8 million episodes 
(19·7–31·4) and 76 600 deaths (55 100–103 500) annually.4 
To date, no global burden estimate has been reported for 
parainfluenza virus and metapneumovirus.
Seasonality information of influenza virus, respiratory 
syncytial virus, parainfluenza virus, and metapneumo­
virus is important in health services planning and the 
development of appropriate disease prevention and 
control strategies, including immunisation strategies. 
The demand for a global overview of the seasonal 
patterns of these four main viruses has been growing 
steadily because it helps to understand the seasonality in 
those under­reported countries or regions where the 
burden of viral respiratory infections is substantial while 
health­care resources are insufficient. For example, the 
seasonality of one country could be possibly estimated 
given the information of countries in geographical 
proximity or any other global patterns. As a result, several 
reports5–15 have described the global seasonality of 
influenza virus and respiratory syncytial virus (appendix 
pp 9–11). In these studies, both influenza virus and 
respiratory syncytial virus circulation peaks were well 
aligned with winter months in temperate regions, while 
greater diversity in timing was observed in the tropics; 
and both viruses showed weak latitudinal gradients in 
the annual timing of epidemics by hemisphere, with 
peaks occurring later with increasing latitude. However, 
seasonal patterns of these two viruses are still poorly 
understood in tropical and subtropical regions where 
seasonal patterns could not be well described simply by 
indicators, such as peak timing or beginning and end of 
epidemics, as done in temperate regions. Only three 
studies5,7,10 reported monthly country­level activity of 
influenza virus; nevertheless, these reports were unable 
to characterise any within­country variations that could 
help to understand the latitudinal gradient of viral 
activity. In addition to the seasonal patterns reported, 
some studies6,8,14 reported pronounced correlations 
between meteorological factors, such as temperature and 
humidity, and influenza virus epidemics, suggesting the 
possibility in prediction of viral epidemics on a global 
scale. However, issues related to data availability impeded 
Research in context
Evidence before this study
We searched PubMed for any studies published between 
Jan 1, 2000, and Nov 30, 2018, that reported global 
seasonality of influenza virus, respiratory syncytial virus, 
parainfluenza virus, or metapneumovirus, using the search 
terms “(influenza OR RSV OR respiratory syncytial virus OR 
parainfluenza OR PIV OR metapneumovirus OR MPV) AND 
(seasonal* OR activity) AND (global OR worldwide)”. We 
identified 11 studies reporting global seasonality, including 
one reporting influenza virus and respiratory syncytial virus, 
eight reporting influenza virus, and two studies reporting 
respiratory syncytial virus; no studies were found reporting 
global metapneumovirus or parainfluenza virus seasonality. 
According to these studies, both influenza virus and 
respiratory syncytial virus peaks were well aligned with winter 
months in temperate regions, while greater diversity in timing 
was observed in the tropics; both viruses presented weak 
latitudinal gradients in the annual timing of epidemics by 
hemisphere, with peaks occurring later with increasing 
latitude. Eight of 11 studies were based on country-level data 
and thus were unable to account for subcountry-level 
variations, whereas the remaining three studies only reported 
the peak or onset month of the epidemics. In addition to 
seasonality results, three of 11 studies reported the correlation 
between meteorological factors, such as temperature and 
humidity, and influenza virus epidemics, suggesting the 
possibility in predicting viral epidemics globally. However, 
issues related to data availability impeded these studies from 
looking further into the prediction of viral epidemics.
Added value of this study
To our knowledge, this is the first systematic analysis of global 
monthly activity of influenza virus, respiratory syncytial virus, 
parainfluenza virus, and metapneumovirus at both country 
and subcountry levels. On a global scale, we modelled the 
association between temperature and relative humidity and 
the activity of influenza virus and respiratory syncytial virus. 
We also developed an online interactive tool for predicting 
local epidemic months and we predicted the global monthly 
epidemics of influenza virus and respiratory syncytial virus on a 
5° by 5° grid.
Implications of all the available evidence
The seasonality information of influenza virus, respiratory 
syncytial virus, parainfluenza virus, and metapneumovirus is 
key for health services planning. The prediction tool developed 
in our study is helpful in predicting the onset months of local 
influenza virus and respiratory syncytial virus epidemics, and it 
serves as a supplement to existing surveillance. This tool, 
together with the summarised seasonality information, will 
help with the optimisation of respiratory syncytial virus 
immunisation strategies that rely on the information of local 
respiratory syncytial virus season, especially in most 
middle-income and lower-income countries where routine 
respiratory syncytial virus surveillance is not available.
See Online for appendix
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these studies from looking further into the prediction of 
viral epidemics.
To address the data gaps in global seasonality of 
influenza virus, respiratory syncytial virus, parainfluenza 
virus, and metapneumovirus, we compiled data from 
a systematic literature review, online datasets, and 
unpublished research data at both country level and 
subcountry level, and did a systematic analysis of global 
monthly activity of these four viruses. Furthermore, with 
the compiled dataset, we aimed to model viral epidemics 
on a monthly basis using site­specific meteorological 
predictors.
Methods
Search strategy and selection criteria
We collected viral activity data for influenza virus, 
respiratory syncytial virus, parainfluenza virus, and 
metapneumovirus from a range of sources, including a 
systematic literature search, online public datasets, and 
the research datasets shared by the collaborators from 
Respiratory Syncytial Virus Global Epidemiology Network 
(RSV GEN).16
We searched three bibliographical databases (MEDLINE, 
Embase, and Global Health), for articles reporting activity 
of influenza virus, respiratory syncytial virus, para­
influenza virus, or metapneumovirus using a tailored 
search strategy. The literature search used the terms 
(with synonyms and closely related words) “influenza 
virus”, “respiratory syncytial virus”, “parainfluenza virus”, 
“human metapneumovirus”, and “acute lower respiratory 
infection” combined with “seasonality”, “surveillance”, 
“periodicity”, and “temporal variation” (appendix pp 1–2). 
In the present study, records related to all­cause acute 
lower respiratory tract infection that did not include any of 
the four viruses above were excluded. We limited the 
literature search to the period of Jan 1, 2001, to Dec 31, 2017. 
We did not include studies published before 2000 because 
seasonality could change in the long term and our objective 
was to report on current global seasonality. References 
cited in retrieved articles were also examined for eligibility. 
No language restrictions were applied. Inclusion and 
exclusion criteria can be found in the appendix (p 3).
We included open­access online data from WHO 
FluNet,17 Pan America Health Organization FluID,18 Japan 
National Institute of Infectious Diseases,19 Hong Kong 
Department of Health,20 Canada FluWatch,21 and 
New Zealand Ministry of Health.22 Detailed information 
about these data are in the appendix (p 12). We also 
included viral activity data shared by RSV GEN, which is a 
collaboration of more than 70 investigator groups 
primarily in low­income and middle­income countries 
that was initially established to estimate the disease 
burden of acute lower respiratory tract infection associated 
with respiratory syncytial virus.16 Detailed information on 
RSV GEN data are in the appendix (pp 13–16).
Data extraction was done independently by YL and 
jointly by RMR and XW through a three­stage process, as 
detailed in the appendix (pp 3–4). Any discrepancies were 
resolved through discussion among YL, RMR, and XW. 
The protocol for this systematic literature search is 
registered on PROSPERO (number CRD42018091628).
Quality assessment
For each article included in the systematic literature 
review, a quality assessment was independently done 
by YL and jointly by RMR and XW. The quality assess­
ment comprised three brief questions regarding data 
representativeness, test practice, and timely reporting 
(questionnaire in the appendix [p 4]). Data represen­
tativeness indicated if the seasonality reported in the 
study could be representative of the seasonality in that 
given site. Test practice indicated if there were any 
changes in terms of viral testing during the study period 
that could affect the reported seasonality. Timely 
reporting indicated if issues related to the timing of 
reporting test positives affected the seasonality results. 
Any disagreement was addressed through discussion. 
For each of the three questions, all studies were given a 
rating between A (very good) and D (bad). Any study 
that was rated as D in any of the three questions in the 
quality assessment was excluded.
Data analysis
To ensure good comparisons of the seasonality results 
among all sites, we added the number of cases by month 
across all years reported for each data record. We 
converted any weekly data to monthly data by using the 
R package wktmo before we added these data by month.
We defined geographical regions as temperate (latitude 
less than –23·5° or more than 23·5°) and tropical 
(latitude between –23·5° and 23·5°). We defined 
meteorological seasons as spring (March–May in 
the northern hemisphere; September–November in the 
southern hemisphere), summer (June–August in 
the northern hemisphere; December–February in the 
southern hemisphere), autumn (September–November 
in the northern hemisphere; March–May in the southern 
hemisphere), and winter (December–February in the 
northern hemisphere; June–August in the southern 
hemisphere).
For each month, we calculated annual average 
percentage (AAP) as a measurement of the strength of 
virus activity by the formula:
where i denotes the month and n denotes the number of 
cases. We plotted heat maps displaying the activity of 
influenza virus, respiratory syncytial virus, parainfluenza 
virus, and metapneumovirus in each site sorted by latitude.
In the main analysis, we estimated the duration of 
epidemics by the minimum number of months to account 
for a total AAP of 75%, a modified method based on Caini 
AAPi = × 100%
ni
Σ1   
12ni
Articles
e1034 www.thelancet.com/lancetgh   Vol 7  August 2019
and colleagues.7 The modified method could account for 
sites with more than one season per year. The estimation 
for the duration of epidemics was done by first sorting 
monthly AAP into descending order and then identifying 
the first n months to account for AAP of 75%, with each 
month being an epidemic month and n being the duration 
of epidemics. The onset month of epidemics at each site 
was defined by the first month of the longest consecutive 
epidemic months. We applied Pearson’s correlation to 
assess the correlation between the onset month and the 
latitude and longitude of the sites. To present the 
relationship between latitude and duration of epidemics, 
we plotted duration of epidemics against the latitude of 
the sites using local regression (LOESS) smoothing by 
virus, with the parameter span in LOESS set as 0·60.
We did subgroup analyses, determined a priori, to 
compare the duration of epidemics of viruses of interest 
using the same method as stated above. We prespecified 
three comparison groups: influenza virus subtypes 
(influenza virus A vs influenza virus B), influenza virus 
versus respiratory syncytial virus, and respiratory syncytial 
virus versus metapneumovirus. For each comparison 
group, we did the analyses only among those sites with 
complete data of the viruses in the comparison group.
To study the relationship between seasonal timing of 
the viruses, we did cross­correlation analyses for each 
site between influenza virus A and B, between influenza 
virus and respiratory syncytial virus, and between 
respiratory syncytial virus and metapneumovirus using 
−5 to 5 months of lag (a total of 11 correlation analyses). 
In consideration of the multiple correlation analyses 
within each site, we adjusted the significance level to 
0·004 using the Bonferroni method (0·05/11≈0·004). If 
significant correlation results were observed at a site, 
we reported the lag that maximised the correlation 
coefficient as the difference in timing between the 
viruses. We also calculated the monthly overlapping AAP 
between each pair of viruses stated above and the overall 
annual overlapping AAP.
For each site included, we extracted meteorological 
data from the site’s nearest weather station provided by 
the US National Centers for Environmental Information 
using R package GSODR. We modelled monthly AAP of 
virus activity using mean­centred monthly temperature 
and relative humidity as predictors in a LOESS model. 
This model is based on the assumption that for each 
month, the relative strength of viral activity (ie, AAP) is 
associated with the relative measurements of the selected 
meteorological factors (ie, mean­centred temperature 
and relative humidity). Details of model assumption, 
data preparation, model comparison, and model 
assessment are in the appendix (pp 5–6). The model­
predicted AAP values for each site were then used to 
calculate the epidemic months (ie, a dichotomous result 
for each month, epidemic, or non­epidemic). We 
required a minimum of 120 sites with 100 or more 
positives per virus for more robust models. With the 
available data, we were able to model influenza virus 
(including influenza virus subtypes) and respiratory 
syncytial virus only.
To assess the model performance, we predicted the 
monthly AAP at each site using the model trained by 
data from the remainder sites (ie, leave­one­out method) 
as the first step; on the basis of the predicted AAP, we 
then calculated the epidemic months and assessed the 
agreement between the predicted epidemic months and 
the observed epidemic months by calculating Cohen’s κ, 
sensitivity, specificity, positive predictive value, and 
negative predictive value. We also calculated the mean 
difference in months between the predicted and the 
observed onset of epidemics (ie, prediction error) and 
its 95% CI.
On the basis of the model, we estimated the global 
epidemic months of influenza virus and respiratory 
syncytial virus on a 5° by 5° scale using gridded 
temperature and relative humidity data in 2013–17 from 
the HadISDH dataset (4.0.0.2017f).23,24 Moreover, using 
the R package Shiny, we developed an online interactive 
tool for the prediction of local epidemic months of 
influenza virus and respiratory syncytial virus. The user 
manual of this tool is in the appendix (pp 7–8).
All data analyses were done using R software 
(version 3.4.3). The seasonality data and key R functions 
developed for the analysis are available through the 
Edinburgh DataShare.25
Role of the funding source
The funder had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
We initially identified 37 335 studies via our literature 
search. After excluding duplicates, the systematic 
literature search identified 21 065 records, of which 
1081 (5·1%) full­texts articles were assessed for eligibility. 
542 (50·1%) studies were further checked for availability 
of monthly data and for any duplicate data. A total of 
185 (17·1%) studies  were included at the final stage of 
the literature review (appendix p 69); details of these 
studies and their quality assessment results can be found 
in the appendix (pp 17–39). We included 246 sites for 
influenza virus, 183 sites for respiratory syncytial virus, 
83 sites for parainfluenza virus, and 65 sites for 
metapneumovirus. The number of positives, and length 
in years of data from the published literature and other 
sources are in the appendix (p 40). Compared with data 
from the published literature, data from other sources 
had a greater number of positive samples and were 
collected over a longer time­span. The geographical 
distribution of the sites included was mapped and 
categorised by virus (figure 1 shows influenza virus, 
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respiratory syncytial virus, parainfluenza virus, and 
metapneumovirus; appendix [p 70] shows influenza virus 
subtypes). Influenza virus A (H1N1) was not included in 
the analysis due to the small number of sites included 
(n=39).
Figure 2 shows the global monthly activity of influenza 
virus, respiratory syncytial virus, parainfluenza virus, 
and metapneumovirus by latitude (results of influenza 
virus subtypes the appendix pp 71–72). Animated figures 
of global monthly activity of these four viruses can be 
found in the ShinyApp. Distinct season ality of virus 
activity was observed in most sites for the four viruses. 
Latitudinal variations of the onset month of epidemics 
were also observed, although patterns varied by virus. 
Detailed results of epidemic months grouped by country 
are in the appendix (pp 41–66).
Influenza virus epidemics occurred consistently during 
January–March in most temperate sites in the northern 
hemisphere and during June–August in most temperate 
sites in the southern hemisphere. These patterns became 
less pronounced closer to the equator, with the emergence 
of summer epidemics in some sites. Variable timing 
of epidemics was observed in tropical sites. In both 
hemispheres, the onset of the major influenza virus 
epidemics was later with increasing latitudes (northern 
hemisphere: r=0·36, p<0·001; southern hemisphere: 
r=0·47, p=0·003).
Respiratory syncytial virus activity showed a latitudinal 
gradient in the timing of epidemics in each hemisphere. 
In the northern hemisphere, respiratory syncytial virus 
activity was initiated in July in tropical sites. The activity 
was initiated later with increasing latitude until it reached 
high­latitude sites around January. Subsequently, the 
respiratory syncytial virus activity started to wane before 
another round of activity was initiated around July in 
tropical sites. Similar patterns were observed in the 
southern hemisphere, where respiratory syncytial virus 
activity was initiated around January in tropical sites 
first and around June in high­latitude sites. Interestingly, 
in the tropics, the timing of respiratory syncytial virus 
epidemics was similar within each hemisphere but 
differed greatly between hemispheres, with only a few 
exceptions in equatorial sites; this pattern was not 
observed with any influenza virus. In both hemispheres, 
the onset of major respiratory syncytial virus epidemics 
was later with increasing latitudes (northern hemi sphere: 
r=0·50, p<0·001; southern hemisphere: r=0·54, p<0·001).
In addition to latitudinal gradients in influenza virus 
and respiratory syncytial virus onset month, we observed 
longitudinal patterns in Europe where most sites had 
similar latitudes but different longitudes. The onset 
month of both influenza virus and respiratory syncytial 
virus epidemics was observed to be later in the east 
(ie, higher longitudes) than the west (influenza virus: 
r=0·46, p=0·006; respiratory syncytial virus: r=0·45, 
p=0·025), while no significant latitudinal patterns were 
observed in this region (influenza virus: r=0·07, p=0·694; 
respiratory syncytial virus: r=0·11, p=0·610). The average 
difference in the timing of onset between the west 
and east of Europe (defined geographically by 20°E) was 
0·6 months for influenza virus and 0·8 months for 
respiratory syncytial virus.
For the animated figures see 
http://resceu.ecdf.ed.ac.uk/
shiny/ShinyGIF/
Figure 1: Study sites included in the analysis
(A) Influenza virus. (B) Respiratory syncytial virus. (C) Parainfluenza virus. (D) Metapneumovirus.
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Seasonality of parainfluenza virus was not as distinct 
as influenza virus or respiratory syncytial virus. 
Parainfluenza virus epidemics were found mostly in 
spring and early summer months in both the northern 
and southern hemi spheres. Metapneumovirus epi­
demics occurred in late winter and spring in most 
temperate sites, but the timing of epidemics was more 
diverse in the tropics.
Overall, virus­specific latitudinal patterns were observed 
in duration of epidemics (appendix p 73). Parainfluenza 
virus had longer duration of epidemics (6·3 months 
[95% CI 6·0–6·7]) than the other three viruses. The 
duration of influenza virus epidemics varied greatly by 
latitude, with shorter duration (3·8 months [3·6–4·0]) 
in temperate sites and longer duration (5·2 months 
[4·9–5·5]) in the tropics. Within influenza virus subtypes, 
influenza virus A(H1N1)pdm had the shortest duration of 
epi demics (3·3 months [3·1–3·5]), followed by influenza 
virus A(H3N2) (4·2 months [3·9–4·4]) and influenza 
virus B (4·5 months [4·3–4·8]), regardless of the latitudes; 
the durations of influenza virus A(H1N1)pdm, A(H3N2), 
and B showed similar latitudinal patterns. Compared 
with influenza virus, the duration of epidemics of 
respiratory syncytial virus and meta pneumovirus was 
stable (respiratory syncytial virus: 4·6 months [4·3–4·8]; 
metapneumovirus: 4·8 months [4·4–5·1]). Subgroup 
analyses using site­matched data replicated the results of 
the comparisons above (appendix pp 74–75).
Results from subgroup analysis using sites with 
complete data of influenza virus A and B showed that 
influenza virus A and B activity were significantly 
correlated in 67 (78%) of 86 temperate sites and 55 (55%) 
of 100 tropical sites. In the temperate region, influenza 
virus A epidemics occurred 0·6 months (95% CI 
0·3 to 0·9) earlier than influenza virus B. In the tropics, 
no clear temporal order was observed (lag=0 [95% CI 
−0·5 to 0·5]) and this lack of clear temporal order was 
largely due to the greater variability in the timing of 
epidemics in the northern tropics (appendix p 76)
Influenza virus and respiratory syncytial virus activity 
were significantly correlated in 28 (67%) of 42 temperate 
sites and 28 (59%) of 47 tropical sites. Influenza 
virus epidemics occurred later than respiratory syncytial 
virus in most temperate sites with the average lag 
of 0·3 months (95% CI −0·3 to 0·9), while no clear 
temporal order was observed in the tropics (lag=0·1 
[−0·9 to 1·2]; appendix p 76).
Respiratory syncytial virus and metapneumovirus 
activity were significantly correlated in 83% of temperate 
sites (29 of 35) and in 62% of tropical sites (14 of 22). In 
the temperate region, metapneumovirus epidemics 
occurred 1·7 months (95% CI 1·1–2·3) later than 
respiratory syncytial virus, while no clear temporal order 
was observed in the tropics (lag=0·2 [95% CI −0·9 to 1·3]; 
appendix p 76)
We found that 61·2% (95% CI 58·6–63·9) of influenza 
virus A and B activity overlapped annually, that 
59·5% (55·4–63·6) of influenza virus and respiratory 
syncytial virus overlapped, and that 60·3% (55·6–65·0) 
of metapneumovirus and respiratory syncytial virus 
overlapped. The percentages did not differ significantly 
between temperate and tropical regions (appendix p 77).
The model with mean­centred temperature and mean­
centred relative humidity was selected for our main 
analysis (detailed results of model comparison and 
selection are in the appendix [pp 67, 78]).
The observed (appendix p 79) and model (figure 3) 
predicted monthly virus activity against mean­centred 
temperature and relative humidity was calculated. Lower 
temperature was associated with higher influenza virus 
and respiratory syncytial virus activity. When temperature 
Figure 2: Heat maps of global monthly activity of influenza virus (A) and respiratory syncytial virus (B), 
parainfluenza virus (C), and metapneumovirus (D), sorted by latitude
AAP=annual average percentage. + denotes the onset month of virus epidemics. 
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was lower than the annual average, higher relative 
humidity was also associated with higher respiratory 
syncytial virus activity but not with higher influenza 
virus activity. When temperature was higher than the 
annual average, higher relative humidity was associated 
with higher influenza virus activity, especially for 
influenza virus A(H3N2), whereas this pattern was not 
observed for respiratory syncytial virus.
Regarding the predictability of the model, the results of 
the leave­one­out cross validation are shown in the 
appendix (p 68). Overall, the model had good accuracy 
across all viruses in predicting local epidemic months. 
Better predictability was observed in the temperate 
regions than in the tropics, especially for influenza virus. 
Regarding the prediction of the onset month of 
epidemics, the model prediction error was –0·2 months 
(95% CI –0·6 to 0·1) for influenza virus and 0·1 months 
(–0·2 to 0·4) for respiratory syncytial virus.
Moreover, on the basis of the model, we present the 
esti mated global epidemic months of influenza virus and 
respiratory syncytial virus on a 5° by 5° scale, including 
the onset of the epidemic months (figure 4; 
supplementary video).
Discussion
To our knowledge, this is the first systematic analysis of 
global monthly activity of influenza virus, respiratory 
syncytial virus, parainfluenza virus, and metapneumo­
virus at national and subnational levels. With strict 
criteria, we compiled laboratory­confirmed viral activity 
from a literature review, online surveillance datasets, and 
shared datasets by collaborators. We present global maps 
of monthly virus activity for influenza virus (including 
types and subtypes), respiratory syncytial virus, para­
influenza virus, and metapneumovirus, showing the 
distinct seasonal patterns for each virus. We found that 
latitudinal patterns in duration of epidemics were diverse 
among the four viruses.
Our results suggest that the global seasonal patterns 
of influenza virus and respiratory syncytial virus are 
different in terms of both timing and duration of 
epidemics. However, in a previous global review by 
Bloom­Feshbach and colleagues,11 the authors concluded 
that seasonal patterns of influenza virus and respiratory 
syncytial virus were broadly similar in timing. The 
difference between the results of our study and those of 
Bloom­Feshbach and colleagues11 is likely to be due to 
the smaller number of sites included in their review 
compared with the present study (influenza virus: 
246 sites vs 77 sites; respiratory syncytial virus: 183 sites 
vs 96 sites).
Our study also found that seasonality was slightly 
different among influenza virus types and subtypes, 
similar to the findings from previous country­level 
regional reports.26,27 In our study, influenza virus A 
epidemics occurred 0·6 months (95% CI 0·3 to 0·9) 
before influenza virus B in the temperate sites but no 
clear temporal order was seen in the tropical sites 
(lag=0 [−0·5 to 0·5]). Moreover, we identified some 
interesting patterns that had not been reported in 
previous reports; the latitudinal patterns of epidemic 
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Figure 3: Model-predicted output of monthly activity of influenza virus and respiratory syncytial virus 
against mean-centred temperature and relative humidity
(A) Influenza virus (B) Influenza virus A. (C) Influenza virus B. (D) Influenza virus A(H1N1)pdm. (E) Influenza 
virus A(H3N2). (F) Respiratory syncytial virus. AAP=annual average percentage.
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(Figure 4 continues on next page)
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Figure 4: Global maps of the 
estimated average epidemic 
months of influenza virus (A) 
and respiratory syncytial 
virus (B) during 2013–17 on a 
5° by 5° scale
−35°
−23·5°
0° 0°
23·5°
35°
January FebruaryB
−35°
−23.5°
23.5°
35°
−35°
−23.5°
23.5°
35°
−35°
−23.5°
23.5°
35°
March April
May June
July August
September October
November December
−35°
−23·5°
0° 0°
23·5°
35°
−35°
−23·5°
0° 0°
23·5°
35°
−35°
−23.5°
23.5°
−23.5°
23.5°
−23.5°
23.5°
35°
−35°
35°
−35°
35°
0°
−35°
−35°
−23·5°
−23·5°
0° 0°
0° 0°
23·5°
23·5°
−35°
−23·5°
0°
23·5°
35°
35°
35°
Non-epidemic Onset Epidemic No data
Articles
www.thelancet.com/lancetgh   Vol 7  August 2019 e1041
duration were similar among influenza virus subtypes, 
with influenza virus A(H1N1)pdm being the most 
seasonal virus (duration of epidemics 3·3 months 
[3·1 to 3·5]), followed by influenza virus A(H3N2) 
(4·2 months [3·9 to 4·4]) and influenza virus B 
(4·5 months [4·3 to 4·8]), regardless of the latitudes.
Compared with influenza virus and respiratory syncytial 
virus, year­round laboratory­confirmed data of meta­
pneumo virus and parainfluenza virus are scarce and 
no global report on the seasonality of these two viruses 
is available. In the present study, we found that 
parainfluenza virus epidemics occurred most often in the 
spring and early summer months in each hemisphere; 
metapneumo virus epidemics occurred in late winter and 
spring in most temperate sites, but the peaks were more 
diverse in the tropics. Parainfluenza virus had longer 
duration of epidemics, which could be explained by the 
different circulation timings in each parainfluenza virus 
subtype.28,29 Metapneumovirus had similar patterns to 
respiratory syncytial virus in duration of epidemics, 
which might reflect known genetic similarities between 
the two viruses.30 However, these two viruses did not 
co­circulate at most sites. In the temperate regions, 
metapneumovirus occurred 1·7 months (95% CI 1·1–2·3) 
after respiratory syncytial virus; in the tropics, no clear 
temporal order was observed. The non­co­circulation 
of respiratory syncytial virus and metapneumovirus 
indicates possible interference between these two viruses 
warranting further study.
The mechanisms that shape the global seasonal 
patterns of influenza virus, respiratory syncytial virus, 
parainfluenza virus, and metapneumovirus remain 
unclear. Possible mechanisms include contact rates 
between susceptible and infected hosts, virus survival, 
and host immunity. Possible seasonal stimuli include 
temperature, humidity, precipitation, solar radiation, 
travel of work flows, and other factors.31 In our study, all 
four viruses had different global patterns of timing and 
duration of epidemics; these patterns are unlikely to be 
well explained by non­virus­specific factors alone, and 
potential spurious correlations between any non­virus­
specific factors and virus activity should be considered. 
For example, travelling pattern is a potential factor that 
affects transmission but is not likely to explain the 
observed seasonal patterns well due to its non­virus­
specific nature. Therefore, we did not select non­
virus­specific factors in our candidate models. The 
two predictors that we included, temperature and relative 
humidity, were associated with the seasonality of 
influenza virus and respiratory syncytial virus in different 
ways. Although lower temperature was associated with 
higher activity of both influenza virus and respiratory 
syncytial virus, higher relative humidity was associated 
with higher influenza virus activity when temperature 
was above annual average and was associated with higher 
respiratory syncytial virus activity when temperature was 
lower than the annual average. Experimental studies on 
the transmission and survival of these viruses are needed 
to confirm our findings. Our findings regarding the 
predictors of influenza virus were similar to the two types 
of influenza virus peaks, “cold­dry” and “humid­rainy”, 
proposed by Tamerius and colleagues.14 However, their 
model was based on the activity of influenza virus of a 
dichotomous nature—ie, peak and non­peak.14 In our 
study, we modelled the activity of influenza virus and 
respiratory syncytial virus in a continuous nature, thus 
allowing for increased flexibility in our prediction.
On the basis of the gridded dataset of monthly 
temperature and relative humidity on a 5° by 5° scale,23,24 
we mapped the global average epidemic months in 
2013–17. The results indicated that for those countries 
with a wide range of climate patterns, the viral epidemics 
varied within the country. For example, influenza virus 
and respiratory syncytial virus epidemics occurred earlier 
in northern Australia than in southern Australia. 
Our study provides global maps of monthly virus 
activity, which have important implications for public 
health strategy. For influenza virus, vaccination is the 
most effective way to prevent disease.32 Seasonality data 
from existing country­level surveillance help to inform 
the timing and composition of influenza virus vaccines, 
but such surveillance is unable to account for any 
with in country variations and undersampled areas. By 
incorporating data from published and unpublished 
studies, our study potentially fills the data gap at 
subnational level and for countries with no surveillance 
programme. This additional knowledge is particularly 
important for geo graphically large countries and tropical 
regions where great variations of virus activity might 
exist, as found in our study. For respiratory syncytial 
virus, the seasonality information is important for 
immunisation strategy. In high­income countries, the 
administration of palivizumab prophylaxis, a respiratory 
syncytial virus­neutralising mono clonal antibody mainly 
used among high­risk infants, needs to be timed 
according to the local respiratory syncytial virus season 
given the short duration of its protection. For middle­
income and lower­income countries, respiratory syncytial 
virus seasonality information is important for the 
development of affordable biological equivalents of 
palivizumab and any vaccines with short duration of 
protection.33 Moreover, the length of a respiratory syncytial 
virus season defined by the duration of epidemics in our 
study is stable at 4–5 months across all sites, by contrast 
with influenza virus, which has irregular seasonality or 
year­round activity in the tropics. This information could 
help optimise immunisation programmes by focusing 
on the predefined respiratory syncytial virus seasons in 
both temperate and tropical regions. Unlike influenza 
virus, for which surveillance data are widely available, 
respiratory syncytial virus surveillance data are still scarce 
and WHO is in the process of implementing a global 
respiratory syncytial virus surveillance pro gramme.34 For 
all the viruses, the seasonality information is helpful in 
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health services planning, especially when viruses co­
circulate and impose pressure on hospital beds. It is also 
important for the patients’ clinical management and for 
the appropriate use of antibiotics in the context of 
increased antimicrobial resistance and insufficient health 
resources in some settings.35
This study, however, is not without its limitations. 
First, similar to most studies of this type, the accuracy of 
the global activity data reported could be limited by the 
variety of methods applied in the studies and surveillance 
systems included. We were also unable to account for 
the variability regarding the age groups and severity of 
viral infections included at each site. Although we 
aspired to have good geographical representation, we 
applied strict inclusion criteria and did additional quality 
assessment to exclude studies in which the reported 
seasonality was likely to be biased by study participants, 
testing practice, or reporting practice. Second, for better 
comparison across different sites, we calculated monthly 
AAP by aggregating multiyear data to establish virus 
activity. Although multiyear surveillance data suggest 
that the year­to­year change of influenza virus and 
respiratory syncytial virus onset is within 1 month for 
most sites,5,12 aggregating multiyear data could obscure 
the seasonal patterns of those sites with more notable 
year­to­year changes in seasonality. In particular, we 
were unable to identify multiyear periodicity of 
respiratory syncytial virus activity, which has been 
reported in some countries in northern Europe.36 Third, 
we were unable to report global seasonal patterns of any 
subtype of respiratory syncytial virus, para influenza 
virus, or metapneumovirus due to a paucity of relevant 
data reported; this exclusion of subtypes could obscure 
the seasonality results of respiratory syncytial virus, 
parainfluenza virus, and meta pneumovirus, particularly 
parainfluenza virus since the seasonal patterns were 
reported to differ greatly by type.28,29 Fourth, compared 
with influenza virus and respiratory syncytial virus, 
fewer sites reported data on meta pneumovirus and para­
influenza virus, thus limiting the representativeness of 
the results. Fifth, we were only able to summarise the 
global seasonality on a monthly basis instead of on a 
weekly basis due to the scarcity of weekly data (eg, only 
20% of respiratory syncytial virus data in our study were 
originally aggregated weekly) and methodological 
challenges to accommodate the different definitions for 
week (eg, a week can start with Saturday, Sunday, or 
Monday by different definitions). Sixth, due to the lack of 
granularity of our training data, our prediction model 
might not be able to reflect the possible changes of viral 
epidemics induced by subtle short­term climate changes. 
However, such prediction is possible with data that are 
more granular in the future (eg, multiyear weekly data). 
Finally, our model is restricted in its ability to predict the 
influenza virus epidemic months in the tropical region, 
partly due to the seasonality being unclear and its 
inablity to establish association between viral activity 
and meteorological factors. In the tropics, multiyear 
viral activity data from more countries are warranted and 
factors related to host immunity (eg, seasonal fluctuation 
of nutritional status)37 can be considered in future 
modelling studies.
Given the substantial health­care burden caused by 
influenza virus, respiratory syncytial virus, parainfluenza 
virus, and metapneumovirus, their seasonal patterns 
described in our study are important for related health 
services planning. The model is helpful in predicting the 
onset months of local influenza virus and respiratory 
syncytial virus epidemics. This model, together with the 
seasonality results presented, helps with the optimisation 
of any respiratory syncytial virus immunisation strategies 
that rely on the information of local respiratory syncytial 
virus season, especially in most middle­income and 
lower­income countries where respiratory syncytial 
virus surveillance might not be routine. Future studies 
should consider describing and modelling the activity of 
influenza virus, respiratory syncytial virus, parainfluenza 
virus, and metapneumovirus on a multiyear scale and 
should take into consideration the effects of climate 
change on respiratory viral epidemic seasonality.
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